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Reciprocal chromosomal translocations are the causative genetic aberration in
almost 60% of cases of pediatric acute myeloid leukemia (AML).1 Among these,
rearrangements of the MLL1/KMT2A gene located on chromosome 11q23 are most
frequent, accounting for almost 25% of pediatric and 50% of infant AML cases.1
The oncogenicity of MLL fusions has been investigated in various mouse models,
including human CD34+ xenografts, which provided strong evidence that MLL
fusion oncogenes are sufficient to transform human hematopoietic stem and pro-
genitor cells (HSPC).2-4 These studies also highlighted the environmental influence
on disease phenotype and the role of the MLL fusion partner on the overall onco-
genicity. However, the results were mainly obtained using retroviral expression sys-
tems, which invariably express one fusion protein at non-physiological levels, and
neglect the loss of the wild-type alleles of both involved genes and a potential con-
tribution of the reciprocal product of the translocation.5,6 Investigation of MLL
rearrangements via knock-in in human HSPC supported their oncogenicity at
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ABSTRACT
endogenous expression levels, however, the loss of one
wild-type allele of each fusion partner, and potential
involvement of a reciprocal fusion product, still remain
elusive with this approach.4 It is therefore desirable to
investigate the oncogenicity of bona fide MLL rearrange-
ments in primary human HSPC both in vitro and in vivo,
which can be facilitated with genome editing technolo-
gies.7-10
The CRISPR-Cas9 system has only recently been suc-
cessfully established to modify functional human
HSPC.11,12 It was shown to allow the generation of chro-
mosomal inversions in vitro9,10,13 and in murine in vivo mod-
els,14 and may thus overcome efficacy hurdles that may
have caused the failure of models based on transcription
activator-like effector nucleases (TALEN).15
While attempts to recapitulate transformation of pri-
mary human HSPC by chromosomal rearrangements in
vitro failed,15 and thereby raised the question of whether
the efficacy of the technology or an inherent protection of
HSPC against chromosomal rearrangements caused the
failure,15,16 in vivo experiments with CRISPR-Cas9-induced
chromosomal translocations in human HSPC may have
the power to answer these open questions, but have not
yet been accomplished.
Here we successfully generated chromosomal
rearrangements (t[11;19]/MLL-ENL) in CD34+ HSPC,
resulting in clonal outgrowth in vitro and monocytic and B-
lineage leukemia in vivo, which we accomplished with an
improved lentiviral CRISPR-Cas9 system to generate
chromosomal rearrangements based on our former
work.17 Furthermore, our study highlights the impact of
non-cell-autonomous signals influencing not only the phe-
notype but the overall transformation of HSPC by MLL
rearrangements. Thus, our study presents the first human
de novo leukemia model with CRISPR-Cas9-engineered
chromosomal translocations and highlights the power of
this advanced approach.
Methods
Plasmids and viral particle production
A detailed description of the vector construction is provided in
the Online Supplementary Methods. CRISPR-Cas9 target sites were
selected using the CCTop selection tool.19 Lentiviral vectors were
provided via Addgene (# 69146-69148, 69212, 69215, 89392-
89395). Lentiviral particles were produced as described before.17
Reporter assay-based testing of the spacers
Reporter-based single-guide RNA (sgRNA) efficacy testing was
performed as described elsewhere.17
Cell culture 
Cell lines were maintained as described in the Online
Supplementary Methods. Human CD34+ cells were isolated from
cord blood using the CD34 MicroBead Kit (Miltenyi Biotec)
according to the manufacturer’s instructions. The cord blood was
provided with the parents’ consent by the Department of
Gynecology and Obstetrics, Hannover Medical School, and
experiments were approved by the local ethics committee.
Details on CD34+ cell maintenance and transduction are
described in the Online Supplementary Methods section.
Colony-forming unit assays were performed according to
manufacturer’s instructions. Upon initial plating, 1x104 cells were
seeded. For replating a total of 3x104 cells per plate were seeded.
Xenotransplantation
All animal experiments were approved by the local
authorities. For transplantation, 4x105 CD34+ cells were pre-
stimulated and transduced as described above. Twenty-four
hours after transduction, the HSPC were transplanted intra-
venously into sublethally irradiated (2.5 Gy) male or female
NSGS mice20 (age: 8-12 weeks).
Flow cytometry
Cells were stained with antibodies specific for human CD45
(APC, V500), CD33 (PE), CD14 (APC-Cy7), CD11b (APC), CD64
(PE), CD117 (PE-Cy7), CD19 (PE-Cy7), CD3 (APC-Cy7), CD10
(BV605), CD20 (V450), CD22 (APC), and CD34 (PerCP-Cy5.5) (all
from BD Biosciences). Dead cells were excluded using 4',6-
diamidin-2-phenylindol (DAPI) counterstaining, where applicable.
Cells were analyzed on a FACS Canto flow cytometer (BD
Biosciences), and data were analyzed with FlowJo V10 software.
RNA extraction and polymerase chain reaction
Total RNA was purified from cells with the RNeasy Micro or
Mini Kit (Qiagen), complementary DNA (cDNA) was synthesized
using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), according to the manufacturer’s instructions. The
primers are summarized in Online Supplementary Table S3.
Genomic DNA extraction and polymerase chain reaction
Genomic DNA was extracted using the QIAmp DNA Mini or
Micro Kit (Qiagen) according to the manufacturer’s protocols.
Detection of the genomic breakpoint polymerase chain reaction
was performed with Extensor 2x Master Mix (Thermo Scientific).
Primers are summarized in Online Supplementary Table S3.
T7 endonuclease I based surveyor assay
Polymerase chain reaction primers containing the on-target and
off-target of MLL and ENL are listed in Online Supplementary Table
S3. The T7 endonuclease I (T7E-I) assay was performed according
to the manufacturer’s protocols (New England Biolabs). Digested
fragments were separated by DNA gel electrophoresis and imaged
with a BioRad GelDoc™ XR+ imaging system. Absolute quantifi-
cation of DNA fragments was done with the Image Lab 3.0 soft-
ware (BioRad). The band intensity of the DNA marker (Thermo
Scientific) was correlated to its specific amount of input, and sub-
sequently, the absolute quantities of all DNA fragments were
defined accordingly and the ratios of cut and uncut fragments were
calculated.
Statistical analysis
Statistical analysis was performed with GraphPad Prism soft-
ware (Graphpad Software). 
Results
Advanced lentiviral dual single-guide RNA 
CRISPR-Cas9 vectors for the generation of 
chromosomal rearrangements
With the aim of elucidating the transformative nature of
endogenous chromosomal rearrangements in primary
human HSPC, we developed an advanced, all-in-one
lentiviral CRISPR-Cas9 system with two sgRNA expression
cassettes (L-CRISPR-CTN=CRISPR-Translocations-
mNeon) (Figure 1A). We introduced an enhanced sgRNA
backbone18 and enhancer elements to boost genomic RNA
production,21 resulting in significantly higher titers as tested
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on multiple hematopoietic cell lines (Figure 1B; Online
Supplementary Figure S1). 
Utilizing fluorescence reporter-based spacer testing
(Online Supplementary Figure S2), we established highly effi-
cient sgRNAs (>80% cleavage activity) targeting
MLL/KMT2A and ENL intronic sequences to generate the
t(11;19)/MLL-ENL translocation (Figure 1C; Online
Supplementary Table S1). To prospectively achieve CRISPR-
Cas9-induced chromosomal rearrangement from a single
vector (Figure 1A), the knock-out efficacy of the various
selected sgRNAs expressed from a H1 promoter was tested.
Only minor, non-significant differences in the cleavage effi-
cacy were detectable with sgRNA expression either from a
H1 or U6 promoter (Figure 1D). Importantly, the activity of
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Figure 1. An improved lentiviral vector system for generation of CRISPR-Cas9-induced chromosomal rearrangements. (A) Schematic presentation of lentiviral vector
architecture including genomic RNA-generating promoter assembly: published architecture (L-CRISPR) (i), improved architecture with cytomegalovirus enhancer
(CMV) and simian virus 40 enhancer (SV40) and exchangeability of the hU6 promoter for a H1 promoter (L40C) (ii), and lentiviral vector for dual sgRNA delivery (L-
CRISPR-CTN (iii). (B) Analysis of viral titers in three independent cell lines with two different sgRNAs and three replicates each. (C) Knock-out efficacies (fluorescence
reporter assay) of sgRNAs targeting intronic sequences of ENL and MLL. Selected sgRNAs are marked. (D) Knock-out efficacies of selected sgRNAs expressed from
a human U6 or H1 promoter, as indicated. Knock-out efficacies of selected sgRNAs in L-CRISPR-CTN dual sgRNA configuration (DV) (neg ctrl= anti-luciferase (Luc)
sgRNA, pos ctrl= Tet2 sgRNA).  (E) T7-endonuclease-I assay for on-target sites and the top five predicted off-target sites in HEL cells (OT-1-OT-5). Indel frequencies at




the sgRNA was retained in the dual sgRNA vector configu-
ration (Figure 1D). No recombination of the integrated
provirus was observed (Online Supplementary Figure S3),
warranting high confidence delivery of both sgRNAs.
Off-target cleavage activity is a major concern with the
application of genome editing, but is mostly abrogated by
three or more mismatches between the spacer and proto-
spacer.22,23 T7E-I assays for the top five off-target sites and
the on-target sites of our pre-selected sgRNAs verified high
on-target and no detectable off-target activity at the
endogenous loci (Figure 1E, Online Supplementary Table S2). 
Based on these results, we tested the generation of chro-
mosomal rearrangements [t[11;19]; L-CRISPR-CTN(11;19)]
in hematopoietic cells (Figure 2A). In L-CRISPR-
CTN(11;19)-transduced K562 cells, we could readily detect
expression of the MLL-ENL and reciprocal ENL-MLL tran-
script in the bulk population (Figure 2B,C). Amplification of
the genomic breakpoint and sequence analysis further veri-
fied polyclonal t(11;19) induction at the targeted genomic
sequences (Online Supplementary Figure S4). We could there-
by establish an all-in-one lentiviral CRISPR-Cas9 system for
the efficient induction of chromosomal translocations (L-
CRISPR-CTN).
L-CRISPR-CTN-induced t(11;19) translocations increase
the re-plating efficiency of primary human hematopoietic
stem and progenitor cells in vitro
To determine the impact of endogenous t(11;19) on
HSPC, we transduced cord blood-derived CD34+ HSPC
(16.6±5.2%, n=10). FACS-sorted cells grown in methylcel-
lulose were tested for MLL-ENL expression at the first re-
plating and transcript identity was validated via sequenc-
ing (Online Supplementary Figure S5). Of note, vector
expression was not monitored over time since genome
editing does not rely on continuous expression of the Cas9
or the sgRNA. In three independent experiments, MLL-
ENLmessenger RNA (mRNA) was detectable, resulting in
a rearrangement efficacy of at least 1.6x10-3 (±0.26x10-3).
Upon serial re-plating we detected the extended plating
capacity of t(11;19)-containing cells (Figure 2D), accompa-
nied by robust expression of the MLL-ENL transcript
(Figure 2E, Online Supplementary Figure S6) and detection
of the genomic breakpoint (Figure 2F, Online Supplementary
Figure S6). The latter was not detectable at the first re-plat-
ing, likely due to lower sensitivity at the genomic level
compared to mRNA expression. Our experiments thus
provide evidence that CRISPR-Cas9-induced t(11;19)
CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations
haematologica | 2017; 102(9) 1561
Figure 2. CRISPR-Cas9-induced MLL-ENL rearrangements cause clonal expansion of human CD34+ hematopoietic stem and progenitor cells. (A) Schematic depic-
tion of CRISPR-Cas9-induced chromosomal rearrangements at the MLL and ENL loci. (B) Reverse transcriptase polymerase chain reaction-based detection of MLL-
ENL transcript in K562 cells. Ctrl = MLL-I9-#1 + Luc sgRNAs. (C) RT-PCR-based detection of reciprocal ENL-MLL transcript in K562 cells. Ctrl = MLL-I9-#1 + Luc
sgRNA. (D) Serial plating of CD34+ HSPC after transduction with L-CRISPR-CTN. (E) Detection of MLL-ENL expression in CD34+ HSPCs at fifth plating. Control (MLL-
I9-#1 + Luc sgRNAs) template from third plating. (F) Detection of the genomic MLL-ENL breakpoint in CD34+ HSPCs at fifth plating (control (MLL-I9-#1 + Luc sgRNAs)
template from second plating) compared to the first plating. (G) Analysis of MLL target genes in MLL-ENL-expressing cells (fifth plating) compared to controls (third






translocations can provide self-renewal capacity to human
HSPC. However, the cord blood CD34+ cells with t(11;19)
formed normal hematopoietic colonies and eventually
ceased proliferating. Results in methylcellulose were fur-
ther supported by the transient clonal outgrowth of MLL-
ENL-expressing cells in one out of four experiments per-
formed in liquid culture (Online Supplementary Figure S7).
Long-term tracking of MLL-ENL-expressing cells in other
experiments without growth advantage indicates the need
for additional stimuli to induce transformation (Online
Supplementary Figure S8A,B). 
When clonal outgrowth was observed it was accompa-
nied by a robust up-regulation of known downstream
effectors of MLL-ENL, such as HOXA9, HOXA10, MEIS1,
and PBX3 (Figure 2G, Online Supplementary Figure S7D),24
which was absent in samples without clonal outgrowth
(Online Supplementary Figure S8C). In contrast to former
studies, genes associated with a leukemic stem cell pheno-
type in mice (CBX5, HMGB3, MYBL2)24 were not upregu-
lated in samples with clonal outgrowth (Online
Supplementary Figure S7D). 
Overall, these experiments underline both the potential
and insufficiencies of endogenous t(11;19) to modulate self-
renewal and growth of human HSPC in vitro. 
This is in line with a recent report on TALEN-induced
MLL rearrangements in CD34+ HSPC in vitro.15 This cumula-
tive evidence points towards a non-cell-autonomous com-
ponent in cellular transformation by MLL rearrangements
beyond phenotypic manifestation.
In vivo environment affects the oncogenic transformation
of primary human hematopoietic stem and progenitor
cells by t(11;19)
To further test this hypothesis, we performed trans-
plantation of freshly-transduced, non-sorted L-CRISPR-
CTN(11;19) and L-CRISPR-CTN(ctrl) CD34+ cells into
immunodeficient mice (Figure 3A, Online Supplementary
Figure S9). At weeks 25, 26, and 27 after transplantation,
three moribund mice were analyzed (Figure 3B). One of
the mice presented with intermediate human engraft-
ment, mixed lineage reconstitution and only moderate
expression of the vector backbone, excluding leukemia as
the cause of sickness (Online Supplementary Figure S10A-
C). Two of the mice presented with a hCD45+CD33+
monocytic phenotype (Figure 3C, Online Supplementary
Figure S10B), robust vector expression (Figure 3C, Online
Supplementary Figure S10B), and the MLL rearrangement
was confirmed by fluorescence in situ hybridization in
cultured cells from one mouse (Figure 3E, MLL-split probe
7% positivity). An excess of monocytic cells with imma-
ture features in the bone marrow was verified by nuclear
staining (>80%, Figure 3D). Severe infiltration of myeloid
cells in the liver further supported hematologic disease
(Figure 3F). Sequence analysis of the genomic MLL-ENL
breakpoints detected in all analyzed mice (diseased and
healthy, Sanger sequencing) indicated a clonal origin and
outgrowth of t(11;19)-containing cells (Figure 3G). MLL-
ENL and ENL-MLL breakpoints (Figure 3H), expression
and identity of MLL-ENL and ENL-MLL transcripts
(Figure 3I, Online Supplementary Figure S11), and presence
of human cells expressing the introduced vector were
confirmed (Figure 3C, Online Supplementary Figures S10
and S12A). Notably, while no correlation between MLL-
ENL expression and human cell content was observed,
MLL-ENL expression significantly correlated with the
percentage of vector-expressing cells, further supporting
our approach (Online Supplementary Figure S12B,C).
To validate a malignant phenotype, secondary trans-
plantation of the monocytic samples was performed,
assuming that healthy committed myelo-monocytic pro-
genitors would fail to engraft, which was indeed the case
for two control mice transplanted with L-CRISPR-
CTN(ctrl)-transduced CD34+ cells (Figure 4A).
Surprisingly, five out of six recipients from both donors
with a monocytic phenotype presented with disease
symptoms 15-16 weeks after transplantation (Figure 4A).
The immature monocytic phenotype was confirmed,
with CD64 expression, absence of CD14 and CD15
expression, and partial CD117 expression by flow cyto-
metric analysis, as well as by morphological analyses of
hepatic infiltration (Figure 4B,C, Online Supplementary
Figure S13). Of note, while disease latency was slightly
shortened (25-26 weeks versus 16-17 weeks), the absence
of blast morphology and CD34 expression indicated no
progression of the monocytic leukemia-like disease to a
more immature AML phenotype, despite the transplanta-
tion-induced stress.  
Next, we asked whether EVI1 expression – an indicator
of stem cell origin in MLL-rearranged leukemia25-27 – and
known downstream MLL targets were deregulated in the
mice. While EVI1 was not detectable in our samples or
MLL-rearranged control cell lines, we found upregulation
of PBX3 in the majority of mice. Some samples also
showed upregulation of HOXA10, MEIS1, and MYB
(Online Supplementary Figure S14).
Our experiments thereby provide compelling evidence
that endogenous t(11;19) can initiate a monocytic leukemia-
like phenotype in our xenotransplantation setting, but lacks
the capacity to initiate an immature AML. The detection of
t(11;19) in non-diseased mice also strongly indicates that
additional events are either required for the development of
frank leukemia or influence the latency of disease appear-
ance.
To test this hypothesis of inherent stress and environ-
mental cues as contributing factors in disease manifestation
caused by t(11;19), we harvested bone marrow from pri-
mary recipients freshly-transplanted with L-CRISPR-
CTN(11;19)- and L-CRISPR-CTN(ctrl)-transduced CD34+
cells 8-10 weeks after transplantation – before the onset of
leukemia – and transplanted the bone marrow into second-
ary recipients. Supposedly-clonal genomic MLL-ENL break-
points were detectable in the bone marrow of two out of
three mice at the time of transplantation (Online
Supplementary Figure S15). 
Indeed, we monitored human cell engraftment in the sec-
ondary animals and observed rapid expansion indicating
leukemic transformation (Figure 4A). Detailed analysis of
the cells revealed the development of B-cell acute lym-
phoblastic leukemia (B-ALL) with expression of CD19,
CD22, CD33 and partial expression of CD20 and CD34
(Figure 4D). Of note, the expression of CD33 is a common
feature of B-ALL cells.28,29
The occurrence of B-ALL was further confirmed by mor-
phological analysis of bone marrow cells showing an excess
of blasts (Figure 4E). The presence of the MLL rearrange-
ment was additionally verified by fluorescence in situ
hybridization (Figure 4F, MLL-split probe 67% positivity).
Interestingly, the genomic MLL-ENL breakpoint revealed
that the leukemic clone developed independently from the
dominant clone in the primary recipients, further support-
J. Reimer et al.
1562 haematologica | 2017; 102(9)
CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations
haematologica | 2017; 102(9) 1563
Figure 3. CRISPR-Cas9-induced MLL-ENL rearrangements are leukemogenic in a CD34+ hematopoietic stem and progenitor cell xenotransplantation model. (A)
Schematic depiction of the xenotransplantation model. (B) Survival of mice transplanted with L-CRISPR-CTN-transduced CD34+ HSPC. Mice that succumbed to non-
hematopoietic disease were censored and are indicated (ticked). (C) Flow cytometric analysis of one mouse with hematopoietic disease compared to a control, with
markers as indicated (ctrl = MLL-I9-#1 + Luc sgRNAs). (D) Bone marrow (BM) cytospin analysis of a diseased mouse (MGG, 1000X). (E) Detection of an MLL translo-
cation with fluorescence in situ hybridization on interphase nuclei (Vysis LSI MLL probe; Abbott Laboratories) in BM cells from one diseased mouse. (F)
Histopathological analysis of liver tissue from a healthy control mouse (ctrl = MLL-I9-#1 + Luc sgRNA) (top) and a mouse with monocytic leukemia-like disease trans-
planted with L-CRISPR-CTN(11;19)-containing CD34+ HSPC (bottom) (HE, 100x). (G) Alignment of Sanger sequencing-derived genomic t(11;19)/MLL-ENL breakpoints
of mice with a detectable MLL-ENL breakpoint. (H) MLL-ENL and ENL-MLL genomic breakpoints detected in the BM of two mice with a monocytic leukemia-like dis-
ease. (I) Expression of the MLL-ENL (left) and reciprocal ENL-MLL (right) fusion genes, measured by quantitative polymerase chian reaction from the BM of mice with
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Figure 4. In vivo environment affects the oncogenic transformation of primary human hematopoietic stem and progenitor cells by t(11;19) (A) Survival of serially
transplanted mice with human cell engraftment. Donor: primary recipients with [L-CRISPR-CTN(11;19)] a monocytic leukemia-like disease (Mono #1/#2), a healthy
mouse with a detectable MLL-ENL breakpoint but no disease in the primary recipient, and two control donors (MLL-I9-#1 + Luc sgRNAs) (n = 3 per donor). (B)
Analysis of bone marrow (BM) cell morphology (left: MGG, 1000x) and liver histopathology (right: HE, 100X) showing severe infiltration of a secondary recipient trans-
planted with monocytic leukemia-like disease cells. (C) Flow cytometry analysis of monocytic leukemia cells for monocytic and progenitor cell surface marker expres-
sion. (D) Flow cytometry analysis of B-ALL cells. (E) Analysis of BM cell morphology (MGG, 1000x) of a secondary recipient with B-ALL. (F) Detection of an MLL translo-
cation with fluorescence in situ hybridization on interphase nuclei of B-ALL cells (Vysis LSI MLL probe; Abbott Laboratories).  (G) Alignment of Sanger sequencing-





ing our hypothesis that environmental signals may alter the
transformation of MLL-ENL-harboring cells (Figure 4G).
Utilizing serial transplantation and tracking of NHEJ-scar-
ring at genomic breakpoints, as with our system, potential-
ly provides a tool to investigate the clonal evolution of
leukemia with potentially variable stress conditions, such as
drug treatments, in vivo.
Discussion
By leveraging CRISPR-Cas9 genome editing, we induced
bona fide chromosomal rearrangements in primary human
HSPC in vivo, resulting in a de novo leukemia-like disease
reflecting all the oncogenic properties of MLL-rearrange-
ments: namely the combined, endogenous expression of
both resulting fusion mRNA and concurrent loss of one
wild-type allele of each fusion partner. To achieve efficient
genome editing in CD34+ HSPC we improved our formerly
constructed lentiviral CRISPR-Cas9 delivery system17 for the
generation of chromosomal translocations and transduction
of cord blood-derived CD34+ HSPC. Successful transduction
of human HSPC with our system reproducibly resulted in
both MLL-ENL and ENL-MLLmRNA expression, providing
strong evidence for the formation of true t(11;19)/MLL-ENL
translocations. Intriguingly, functional studies revealed only
a transient and variable growth advantage affecting the
minority of cultures. No full transformation was observed in
liquid cultures or methylcellulose-based in vitro assays using
CD34+ HSPC, which is in line with a recent study utilizing
TALEN to induce MLL translocations or knock-in of
AF9/ENL cDNA into the MLL locus in CD34+ HSPC.4,15 With
MLL-ENL causing cellular senescence32 and an intrinsic pro-
tection of early HSPC against MLL-ENL transformation,16
MLL rearrangements may only serve as a first hit insufficient
to cause full transformation without additional oncogenic
events. Isolation of clonal lines and testing of additional
cytokine combinations may help to understand the lack of
in vitro transformation in consecutive studies.
Leukemic transformation in patients lacking additional
known driver mutations34 prompted us to hypothesize that
environmental cues may not only affect the phenotype of
MLL rearrangement-induced leukemia,3 but may also deter-
mine the overall transformation capacity. Of note, MLL
rearrangements are particularly frequent in pediatric and
infant AML,1 in which both the environment and the cell of
origin differ from those in adults.35,36 The latter was already
shown to affect the transformation capacity of retrovirally
expressed MLL-AF9.36 Supporting the idea that yet
unknown external stimuli of the in vivo environment alter
transformation permissiveness, we noted successful
engraftment and persistence of t(11;19)-harboring cells after
long-term observation, exceeding the time of the in vitro
experiments. This engraftment culminated in the develop-
ment of a monocytic leukemia-like disease in primary
recipients, contrasting with the lack of transformation in
vitro, despite similar input cell numbers. Taking into account
that leukemic transformation exceeded culture time about
3-fold, the lack of supportive signals for maintaining a pre-
leukemic cell in vitro, or a prolonged time-frame for the
acquisition of additional genetic lesions in vivo could explain
the observed phenomenon, although similar conditions
have been used to transform human HSPC with retroviral
overexpression of MLL fusion oncogenes.2,3 The develop-
ment of B-ALL in secondary recipients of a healthy primary
donor may either indicate a disturbance of cellular home-
ostasis contributing to leukemic outgrowth, or result from
B-ALL having a higher proportion of leukemia-initiating
cells.39 The detection of MLL rearrangements in mice with-
out leukemia-like disease in the same time-frame strongly
indicates a progressive acquisition of cooperating mutations
needed for full leukemic transformation. Sequencing of
NRAS and KRAS hotspots, which are frequently mutated in
MLL-rearranged leukemia,34 did not reveal any mutations
(data not shown). More comprehensive sequencing to detect
additional oncogenic hits, tracking of clonal t(11;19) isolates
in serial transplantations, and a larger cohort are required to
identify cooperating events in the future. 
Former studies have made major contributions to the
understanding of leukemogenesis induced by MLL fusion
oncogenes.2,3,24 However, several aspects may have limited
the grasp on MLL rearrangement-guided leukemogenicity
and could hamper the development of novel treatment
options. First, retroviral expression of MLL fusion onco-
genes poses the risk of overexpression-induced phenotypes,
which may be amplified by the use of murine models over
human xenotransplantation models.2,3 To overcome these
limitations of retroviral studies, another recent study has
utilized TALEN-induced DNA-DSB-supported knock-in of
AF9 and ENL cDNA into the MLL locus in HSPC, thereby
recapitulating endogenous expression of the fusion onco-
gene.4 Yet, lack of expression of the reciprocal fusion gene,
in some cases shown to be essential for the phenotype,5 loss
of one wild-type allele of the fusion partner, potential
effects of the translocation of enhancer elements,40 and
microRNA binding sites in the untranslated region of the
fusion partner can only be covered by the induction of true
chromosomal translocations, as shown in our study.
Furthermore, an excess of input cells insufficiently reflecting
the clonal disease development and homeostatic mecha-
nisms regulating clonal outgrowth in patients could have
influenced the outcomes of former studies, which may be
indicated by our detection of chromosomal translocations
in mice not showing disease.  Notably, CRISPR-Cas9-
induced NHEJ-scaring of the chromosomal breakpoints
allowed tracking of clonal fluctuation and revealed a clonal
shift during leukemic outgrowth in secondary recipients. 
Our study reporting a humanized, CRISPR-Cas9-induced
cancer model with in vivo transformation uncovers new
aspects of the oncogenic potency and limitations of endoge-
nous MLL rearrangements in human HSPC, and advances
disease modeling closer to patient-specific disease progres-
sion than before. Leveraging our approach to generate pre-
cise cancer models with the CRISPR-Cas9 system will
allow more detailed analysis of potential homeostatic
mechanisms and oncogenic cooperations during leukemic
transformation, as well as the development of targeted ther-
apies and investigation of drug resistance mechanisms. 
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